Literature DB >> 9822920

Hep Par 1 and selected antibodies in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma, combined tumours and metastatic carcinoma.

A S Leong1, R T Sormunen, W M Tsui, C T Liew.   

Abstract

AIMS: To examine the usefulness of Hep Par 1 together with selected antibodies in the separation of hepatocellular carcinoma (HCC) from cholangiocarcinoma (CC), combined tumours (HCC-CC) and metastatic carcinoma. METHODS AND
RESULTS: Antibodies to Hep Par 1, CK19, CK20 and factor XIIIa were applied to 32 HCCs, 27 CCs, five HCC-CCs and 19 metastatic carcinomas from a variety of sites. Hep Par 1 produced distinctive granular staining of all benign hepatocytes and stained 30 HCCs in a heterogeneous manner, irrespective of the degree of differentiation. While labelling all cases of combined HCC-CC, the antibody also stained the mucus-secreting cells of four cases of pure CC. Anti-CK19 produced distinctive staining of bile ducts and CC but also decorated four HCCs and 10 metastatic tumours. Factor XIIIa was not found in normal, reactive or neoplastic hepatocytes. CK20 was found in some cases of HCC and CC and in all cases of metastatic carcinomas from the colon.
CONCLUSIONS: Hep Par 1 was a sensitive marker of hepatocytes but its variable staining in HCC may produce false negative results in small biopsies and it was occasionally found in CC. The highest diagnostic yield was obtained when anti-Hep Par 1, CK19 and CK20 were used in a panel. Factor XIIIa staining has no role in the diagnosis of liver cancers.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9822920     DOI: 10.1046/j.1365-2559.1998.00522.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  25 in total

1.  Surveillance and diagnosis of hepatocellular carcinoma in patients with cirrhosis.

Authors:  Lorenzo Andreana; Graziella Isgrò; Maria Pleguezuelo; Giacomo Germani; Andrew K Burroughs
Journal:  World J Hepatol       Date:  2009-10-31

Review 2.  Combined hepatocellular cholangiocarcinoma: a case report and review of literature.

Authors:  Shailender Singh; Subhankar Chakraborty; Neelima Bonthu; Stanley Radio; Shahid M Hussain; Aaron Sasson
Journal:  Dig Dis Sci       Date:  2013-02-09       Impact factor: 3.199

3.  Characterization of a new rat cell line established from 2'AAF-induced combined hepatocellular cholangiocellular carcinoma.

Authors:  R Gil-Benso; A Martinez-Lorente; A Pellin-Perez; S Navarro-Fos; M A Gregori-Romero; C Carda; R Callaghan; A Peydro-Olaya; A Llombart-Bosch
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001-01       Impact factor: 2.416

4.  Canalicular immunostaining of aminopeptidase N (CD13) as a diagnostic marker for hepatocellular carcinoma.

Authors:  C Röcken; J Licht; A Roessner; S Carl-McGrath
Journal:  J Clin Pathol       Date:  2005-10       Impact factor: 3.411

5.  Elevated hepatocyte paraffin 1 and neprilysin expression in hepatocellular carcinoma are correlated with longer survival.

Authors:  David Mondada; Fredrik T Bosman; Charlotte Fontolliet; Walter K F Seelentag
Journal:  Virchows Arch       Date:  2005-10-12       Impact factor: 4.064

6.  Intramucosal stomach adenocarcinoma metastasizing as a large intraabdominal mass with focal choriocarcinomatous differentiation.

Authors:  Yukio Fujiyoshi; Shuying Jiang; Xia Feng
Journal:  Int J Clin Exp Pathol       Date:  2012-10-01

7.  Leptin enhances cholangiocarcinoma cell growth.

Authors:  Giammarco Fava; Gianfranco Alpini; Chiara Rychlicki; Stefania Saccomanno; Sharon DeMorrow; Luciano Trozzi; Cinzia Candelaresi; Julie Venter; Antonio Di Sario; Marco Marzioni; Italo Bearzi; Shannon Glaser; Domenico Alvaro; Luca Marucci; Heather Francis; Gianluca Svegliati-Baroni; Antonio Benedetti
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

8.  Cerebral metastasis from hepatoid adenocarcinoma of the stomach.

Authors:  Sheng Zhang; Mi Wang; Yi-Hui Xue; Yu-Peng Chen
Journal:  World J Gastroenterol       Date:  2007-11-21       Impact factor: 5.742

9.  A novel diagnostic marker, p28GANK distinguishes hepatocellular carcinoma from potential mimics.

Authors:  Xiaoyong Fu; Lu Tan; Shuqin Liu; Honghai Li; Lei Chen; Jianmin Qin; Mengchao Wu; Hongyang Wang
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-19       Impact factor: 4.553

10.  Hep Par 1 expression in carcinoma of the cervix: implications for diagnosis and prognosis.

Authors:  T P Thamboo; A Wee
Journal:  J Clin Pathol       Date:  2004-01       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.